Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences.

Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, Pavkov ME, Jordan R, Hailpern SM, Schoolwerth AC, Williams DE; Centers for Disease Control and Prevention CKD Initiative.

Am J Kidney Dis. 2010 Mar;55(3):452-62. doi: 10.1053/j.ajkd.2009.11.016. Epub 2010 Feb 8.

PMID:
20116911
2.

A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.

Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, Pavkov ME, Jordan R, Hailpern SM, Schoolwerth AC, Williams DE; Centers for Disease Control and Prevention CKD Initiative.

Am J Kidney Dis. 2010 Mar;55(3):463-73. doi: 10.1053/j.ajkd.2009.11.017. Epub 2010 Feb 8.

PMID:
20116910
3.

The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative.

Hoerger TJ, Simpson SA, Yarnoff BO, Pavkov ME, Ríos Burrows N, Saydah SH, Williams DE, Zhuo X.

Am J Kidney Dis. 2015 Mar;65(3):403-11. doi: 10.1053/j.ajkd.2014.09.023. Epub 2014 Nov 5.

PMID:
25468386
4.

Screening for chronic kidney disease: which strategy?

Hallan SI, Stevens P.

J Nephrol. 2010 Mar-Apr;23(2):147-55. Review.

PMID:
20155721
5.

Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.

Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, de Jong PE, Postma MJ; Prevention of Renal and Vascular End Stage Disease Study Group.

Clin Ther. 2010 Jun;32(6):1103-21. doi: 10.1016/j.clinthera.2010.06.013.

PMID:
20637965
6.

Population based screening for chronic kidney disease: cost effectiveness study.

Manns B, Hemmelgarn B, Tonelli M, Au F, Chiasson TC, Dong J, Klarenbach S; Alberta Kidney Disease Network.

BMJ. 2010 Nov 8;341:c5869. doi: 10.1136/bmj.c5869.

7.

Validation of the kidney failure risk equation in European CKD patients.

Peeters MJ, van Zuilen AD, van den Brand JA, Bots ML, Blankestijn PJ, Wetzels JF; MASTERPLAN Study Group.

Nephrol Dial Transplant. 2013 Jul;28(7):1773-9. doi: 10.1093/ndt/gft063. Epub 2013 May 3.

PMID:
23645476
8.

Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline.

Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ.

Ann Intern Med. 2012 Apr 17;156(8):570-81. doi: 10.7326/0003-4819-156-8-201204170-00004. Review.

PMID:
22508734
9.

Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.

Rutkowski M, Mann W, Derose S, Selevan D, Pascual N, Diesto J, Crooks P.

Am J Kidney Dis. 2009 Mar;53(3 Suppl 3):S86-99. doi: 10.1053/j.ajkd.2008.07.052.

PMID:
19231766
10.

Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.

Kessler R, Keusch G, Szucs TD, Wittenborn JS, Hoerger TJ, Brügger U, Wieser S.

Swiss Med Wkly. 2012 Feb 3;142:w13508. doi: 10.4414/smw.2012.13508.

11.

The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.

Yarnoff BO, Hoerger TJ, Simpson SK, Leib A, Burrows NR, Shrestha SS, Pavkov ME; Centers for Disease Control and Prevention CKD Initiative.

BMC Nephrol. 2017 Mar 13;18(1):85. doi: 10.1186/s12882-017-0497-6.

12.

[Advanced chronic kidney disease].

Alcázar Arroyo R, Orte Martínez L, Otero González A.

Nefrologia. 2008;28 Suppl 3:3-6. Spanish.

13.

Factors associated with kidney disease progression and mortality in a referred CKD population.

Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O'Donoghue DJ, Foley RN, Middleton RJ.

Am J Kidney Dis. 2010 Dec;56(6):1072-81. doi: 10.1053/j.ajkd.2010.06.010. Epub 2010 Aug 8. Erratum in: Am J Kidney Dis. 2012 Mar;59(3):474.

PMID:
20692750
14.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.

Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007751. doi: 10.1002/14651858.CD007751.pub2. Review.

PMID:
21975774
15.

A predictive model for progression of chronic kidney disease to kidney failure.

Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS.

JAMA. 2011 Apr 20;305(15):1553-9. doi: 10.1001/jama.2011.451. Epub 2011 Apr 11.

PMID:
21482743
16.

Risk of cardiovascular disease in kidney donors as a chronic kidney disease cohort.

Naganuma T, Takemoto Y, Taiyou O, Hirokazu T, Masaki M, Maeda S, Nakatani T.

Mol Med Rep. 2012 Jan;5(1):7-11. doi: 10.3892/mmr.2011.629. Epub 2011 Oct 12.

PMID:
21993905
17.
18.

Cost-effectiveness of primary screening for CKD: a systematic review.

Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, Tangri N.

Am J Kidney Dis. 2014 May;63(5):789-97. doi: 10.1053/j.ajkd.2013.12.012. Epub 2014 Feb 12. Review.

PMID:
24529536
19.

Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000.

Nickolas TL, Frisch GD, Opotowsky AR, Arons R, Radhakrishnan J.

Am J Kidney Dis. 2004 Aug;44(2):185-97.

PMID:
15264176
20.

Prognosis of CKD patients receiving outpatient nephrology care in Italy.

De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, Santoro D, Giancaspro V, Abaterusso C, Gallo C, Conte G, Minutolo R; SIN-TABLE CKD Study Group.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2421-8. doi: 10.2215/CJN.01180211. Epub 2011 Aug 4.

Supplemental Content

Support Center